Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis

Eli Lilly and Company LLY and Incyte Corporation INCY today announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in Rome June 10-13. Lilly and Incyte previously released positive topline results for the RA-BEACON and RA-BUILD studies, both of which met their primary endpoint of ACR20 at 12 weeks as compared to placebo. "Incyte is committed to translating R&D excellence into new medicines, and we are very pleased with the initial results from the Phase 3 trials program of baricitinib," said Rich Levy, M.D., chief drug development officer at Incyte Corporation. "With the prevalence of rheumatoid arthritis worldwide, Lilly is excited to share further information about baricitinib with the scientific community,"said David Ricks, Lilly senior vice president, and president of Lilly Bio-Medicines. "Lilly remains committed to following the science to challenge convention and continuously improve outcomes." Abstracts being presented are highlighted below or can be accessed on the EULAR website at http://www.congress.eular.org. "Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, See full press release